Finally, we discussed the clinical transformation prospects and technical limitations of MAMs-associated proteins (such as MFN2, FUNDC1, and GSK3β) as potential therapeutic targets for DCM. This evidence concerns the gene MFN2 and familial dilated cardiomyopathy.